Replies to post #104783 on Avid Bioservices Inc (CDMO)

[volgoat]

Threaten PPHM?

But I thought PPHM was a scam? What is there to threaten then?

LOL....Make up your mind, Fools.....

[freethemice]

Abraxane is just another form of paclitaxel. Not a threat to Bavituximab. It might work as a combination
with carboplatin and Bavi in first-line NSCLC. http://en.wikipedia.org/wiki/Abraxane
Here is the report on the phase 3 of Abraxene with carboplatin in first-line NSCLC.
It did not improve OS significantly over regular paclitaxel (solvent based).
http://www.ncbi.nlm.nih.gov/pubmed/22547591
J Clin Oncol. 2012 Jun 10;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848. Epub 2012 Apr 30.
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin
as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P,
Zhang H, Iglesias JL, Renschler MF.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
PURPOSE:
This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus
carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced non-small-cell lung cancer (NSCLC).

PATIENTS AND METHODS:
In all, 1,052 untreated patients with stage IIIB to IV NSCLC were randomly assigned 1:1 to receive
100 mg/m(2) nab-paclitaxel weekly and carboplatin at area under the concentration-time curve
(AUC) 6 once every 3 weeks (nab-PC) or 200 mg/m(2) sb-paclitaxel plus carboplatin AUC 6 once
every 3 weeks (sb-PC). The primary end point was objective overall response rate (ORR).

RESULTS:
On the basis of independent assessment, nab-PC demonstrated a significantly higher ORR than sb-PC
(33% v 25%; response rate ratio, 1.313; 95% CI, 1.082 to 1.593; P = .005) and in patients with squamous
histology (41% v 24%; response rate ratio, 1.680; 95% CI, 1.271 to 2.221; P < .001). nab-PC was as effective
as sb-PC in patients with nonsquamous histology (ORR, 26% v 25%; P = .808). There was an approximately
10% improvement in progression-free survival (median, 6.3 v 5.8 months; hazard ratio [HR], 0.902;
95% CI, 0.767 to 1.060; P = .214) and overall survival (OS; median, 12.1 v 11.2 months; HR, 0.922;
95% CI, 0.797 to 1.066; P = .271) in the nab-PC arm versus the sb-PC arm, respectively.
Patients = 70 years old and those enrolled in North America showed a significantly increased OS
with nab-PC versus sb-PC. Significantly less grade = 3 neuropathy, neutropenia, arthralgia, and myalgia
occurred in the nab-PC arm, and less thrombocytopenia and anemia occurred in the sb-PC arm.

CONCLUSION:
The administration of nab-PC as first-line therapy in patients with advanced NSCLC was efficacious
and resulted in a significantly improved ORR versus sb-PC, achieving the primary end point. nab-PC produced
less neuropathy than sb-PC.